NICE update: CDF approval for breast cancer treatment
During December and January, NICE published a further seven technology appraisals, one medical technology and two guidelines, writes Gary Shield.
The guidelines – Acute kidney injury: prevention, detection and management (NG148) and Indoor air quality at home(NG149) – are supported by resource impact statements that detail why implementing the guidelines are not expected to lead to a significant resource impact.
All seven technology appraisals had positive recommendations, with Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619 ) being recommended for use with the Cancer Drugs Fund (CDF). It is estimated that up to 3,300 women per year will be eligible for this treatment, which is for those who have already had endocrine therapy.
Palbociclib joins two other NICE-approved drugs – ribociclib and abemaciclib – at this stage of treatment. Taken once-daily in pill form, palbociclib is a type of drug called a cyclin-dependent kinase 4 and 6 (CDK4/6)
inhibitor. These work by inhibiting proteins in cancer cells, thereby preventing the cells from dividing and growing.
Implementing the medical technology guidance GammaCore for cluster headache (MTG46) is not expected to lead to a significant resource impact.
Gary Shield is resource impact assessment manager at NICE
Related content
The value masterclass shares examples of organisations and systems that have pursued a value-driven approach and the results they have achieved.
This webinar series offers colleagues of ICS organisations the opportunity to discuss common priorities, challenges, and successes within their field.